Drug intelligence / Profile preview

interferon alfa + pegylated interferon alfa

Development stage
Unknown
Lead developer
Roche
Modality
PEGylated Peptides → Modified Peptides → Peptides, Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration
Subcutaneous
01

Overview

Interferon alfa refers to a family of recombinant or naturally occurring cytokines with antiviral and immunomodulatory properties. Pegylated interferon alfa (peginterferon alfa) is a modified form in which polyethylene glycol (PEG) is covalently attached to the interferon molecule. This modification extends the half-life and allows for less frequent dosing compared to conventional (non-pegylated) interferons. Both forms act by binding to type 1 human interferon receptors on cell surfaces, activating the JAK/STAT signaling pathway and inducing expression of genes involved in antiviral defense and immune regulation. These drugs have been foundational therapies for chronic hepatitis C virus (HCV) infection—often in combination with ribavirin—and are also used for chronic hepatitis B virus infection[1][2][3][8]. The introduction of direct acting antivirals has reduced their use as first-line therapy.

Brand names
Pegasys ProClick AutoinjectorPegasys Prefilled Syringe
Other names
IFN-alphaPEG-IFN-alpha
02

Targets

IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR1 (Interferon alpha/beta receptor 1)

Beyond the preview

Go deeper on interferon alfa + pegylated interferon alfa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on interferon alfa + pegylated interferon alfa.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call